©The Author(s) 2026.
World J Clin Cases. Jan 16, 2026; 14(2): 117140
Published online Jan 16, 2026. doi: 10.12998/wjcc.v14.i2.117140
Published online Jan 16, 2026. doi: 10.12998/wjcc.v14.i2.117140
Table 2 Proposed mechanisms of azole-induced male hypogonadism
| Drugs | Mechanism | Clinical manifestation |
| Ketoconazole[46,54] | Inhibition of 17-alpha hydroxylase and 17,20 lyase | Decreased libido |
| Increased estrogen: Testosterone ratio | Gynecomastia | |
| Binding to androgen receptor | Oligospermia; azoospermia | |
| Posaconazole[52] | Inhibition of 11-β hydroxylase | Gynecomastia |
| Compensatory increase in steroidogenesis | ||
| Peripheral aromatization of testosterone to estrogen | ||
| Inhibition of CYP3A4 and CYP3A7 slows down the hepatic metabolism of estrogen | ||
| Itraconazole[49] | Unknown | Gynecomastia |
| Loss of libido |
- Citation: Thakkar S, Kantroo V, Nagendra L, Dutta D, Kamrul-Hasan ABM, Kalra S, Bhattacharya S. Endocrine consequences of antifungal therapy: A missed entity. World J Clin Cases 2026; 14(2): 117140
- URL: https://www.wjgnet.com/2307-8960/full/v14/i2/117140.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v14.i2.117140